22751-23-1

Usage

Uses

Used in Organic Synthesis:
(2-nitrophenyl)acetyl chloride is utilized as a key intermediate in the synthesis of various organic compounds, particularly for the preparation of pharmaceuticals and agrochemicals. Its unique chemical properties, stemming from the presence of the nitro group, make it a versatile building block in the creation of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (2-nitrophenyl)acetyl chloride is employed as a synthetic precursor for the development of new drugs. Its reactivity allows for the formation of a wide range of chemical bonds, facilitating the production of diverse medicinal compounds with potential therapeutic applications.
Used in Agrochemical Industry:
Similarly, in the agrochemical industry, (2-nitrophenyl)acetyl chloride serves as a crucial intermediate for the synthesis of various agrochemicals, including pesticides and herbicides. Its role in the development of these products is essential for enhancing agricultural productivity and crop protection.
Used in Research and Development:
(2-nitrophenyl)acetyl chloride is also used in research and development settings, where its unique properties are explored for potential applications in new chemical reactions and processes. Its presence in the laboratory allows scientists to investigate novel synthetic pathways and develop innovative methodologies in organic chemistry.

Upstream product

• 3740-52-1 2-(2-nitrophenyl)acetic acid 

Downstream Products

• 73903-39-6 N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-2-(2-nitrophenyl)acetamide 
• 875838-75-8 N-[(2-nitro-phenyl)-acetyl]-anthranilic acid 
• 6258-54-4 p'-dimethylamino-o-nitrophenylacetanilide 
• 349135-30-4 N-[(2-nitro-phenyl)-acetyl]-anthranilic acid amide 
• 299419-90-2 N-[(2-nitro-phenyl)-acetyl]-anthranilic acid methyl ester 
• 28565-97-1 N-(2-nitro-phenylacetyl)-anthranilic acid ethyl ester 
• 25888-16-8 4-[(2-nitro-phenyl)-acetyl]-morpholine 
• 4212-33-3 2-(2-nitrophenyl)-1-phenylethanone 
• 74965-87-0 2,2-dimethyl-5-(2-phenylacetyl)-1,3-dioxane-4,6-dione 
• 121989-44-4 N-Methoxy-2-(2-nitro-phenyl)-acetamide 
• 133700-68-2 N-<2-<2,3-dimethoxy-5-(benzyloxy)phenyl>-2-methoxyethyl>-2-nitrophenylacetamide 
• 130109-39-6 2-(2-Nitro-phenyl)-1-(1-pyrrolidin-1-ylmethyl-3,4-dihydro-1H-isoquinolin-2-yl)-ethanone 
• 31142-60-6 2-(2-nitrophenyl)acetamide 
• 88499-50-7 2-nitrobenzeneacetic acid 2-<(2-nitrophenyl)acetyl>hydrazide 

Relevant academic research and scientific papers

Asymmetric Total Synthesis of (-)-Leuconoxine via Chiral Phosphoric Acid Catalyzed Desymmetrization of a Prochiral Diester

The asymmetric total synthesis of (-)-leuconoxine has been achieved. The desymmetrization of a prochiral diester using a chiral phosphoric acid catalyst produced a highly enantioenriched lactam with excellent yield. The ring construction featuring an intr

Identification of Diketopiperazine-Containing 2-Anilinobenzamides as Potent Sirtuin 2 (SIRT2)-Selective Inhibitors Targeting the "selectivity Pocket", Substrate-Binding Site, and NAD+-Binding Site

The NAD+-dependent deacetylase SIRT2 represents an attractive target for drug development. Here, we designed and synthesized drug-like SIRT2-selective inhibitors based on an analysis of the putative binding modes of recently reported SIRT2-selective inhibitors and evaluated their SIRT2-inhibitory activity. This led us to develop a more drug-like diketopiperazine structure as a "hydrogen bond (H-bond) hunter" to target the substrate-binding site of SIRT2. Thioamide 53, a conjugate of diketopiperazine and 2-anilinobenzamide which is expected to occupy the "selectivity pocket" of SIRT2, exhibited potent SIRT2-selective inhibition. Inhibition of SIRT2 by 53 was mediated by the formation of a 53-ADP-ribose conjugate, suggesting that 53 is a mechanism-based inhibitor targeting the "selectivity pocket", substrate-binding site, and NAD+-binding site. Furthermore, 53 showed potent antiproliferative activity toward breast cancer cells and promoted neurite outgrowth of Neuro-2a cells. These findings should pave the way for the discovery of novel therapeutic agents for cancer and neurological disorders.

Exploring of indole derivatives for ESIPT emission: A new ESIPT-based fluorescence skeleton and TD-DFT calculations

Appropriate synthesis methods gave six different indole derivatives substituted at the C-2 or C-3 position. ESIPT emission capacities of these derivatives were investigated. It was concluded that the indole derivative containing the 1,2-dicarbonyl group at the C-2 position has ESIPT emission. Although adding water to the DMSO solution of the ESIPT-based molecule (9:1) resulted in ESIPT quenching, steady-state measurements in MeOH did not occur ESIPT quenching. TD-DFT calculation for uncovering the ESIPT mechanism emerged that the ESIPT mechanism occurred as a barrierless process. The X-ray analysis and DFT conformational analysis revealed that NH and CO groups involving proton transfer mechanisms are in the cis position. A mono-exponential decay was observed in DMSO and MeOH solutions, in which lifetimes were measured as 6.1 and 5.5 ns, respectively. pH studies revealed that acidic and basic solutions of molecule 7 did not influence ESIPT emission.

Visible-Light-Mediated Strategies to Assemble Alkyl 2-Carboxylate-2,3,3-Trisubstituted β-Lactams and 5-Alkoxy-2,2,4-Trisubstituted Furan-3(2H)-ones Using Aryldiazoacetates and Aryldiazoketones

Two new visible-light-mediated strategies are described starting from aryldiazoacetates. The first approach describes their reaction with azides to afford the corresponding imines, and then reaction with aryldiazoketones produces alkyl 2-carboxylate-2,3,3

N-monoarylacetothioureas as potent urease inhibitors: synthesis, SAR, and biological evaluation

A urease inhibitor with good in vivo profile is considered as an alternative agent for treating infections caused by urease-producing bacteria such as Helicobacter pylori. Here, we report a series of N-monosubstituted thioureas, which act as effective urease inhibitors with very low cytotoxicity. One compound (b19) was evaluated in detail and shows promising features for further development as an agent to treat H. pylori caused diseases. Excellent values for the inhibition of b19 against both extracted urease and urease in intact cell were observed, which shows IC50 values of 0.16 ± 0.05 and 3.86 ± 0.10 μM, being 170- and 44-fold more potent than the clinically used drug AHA, respectively. Docking simulations suggested that the monosubstituted thiourea moiety penetrates urea binding site. In addition, b19 is a rapid and reversible urease inhibitor, and displays nM affinity to urease with very slow dissociation (koff=1.60 × 10?3 s?1) from the catalytic domain.

Synthesis and SAR of Tetracyclic Inhibitors of Protein Kinase CK2 Derived from Furocarbazole W16

The serine/threonine kinase CK2 modulates the activity of more than 300 proteins and thus plays a crucial role in various physiological and pathophysiological processes including neurodegenerative disorders of the central nervous system and cancer. The enzymatic activity of CK2 is controlled by the equilibrium between the heterotetrameric holoenzyme CK2α2β2 and its monomeric subunits CK2α and CK2β. A series of analogues of W16 ((3aR,4S,10S,10aS)-4-{[(S)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]carbonyl}-10-(3,4,5-trimethoxyphenyl)-4,5,10,10a-tetrahydrofuro[3,4-b]carbazole-1,3(3aH)-dione ((+)-3 a)) was prepared in an one-pot, three-component Levy reaction. The stereochemistry of the tetracyclic compounds was analyzed. Additionally, the chemically labile anhydride structure of the furocarbazoles 3 was replaced by a more stable imide (9) and N-methylimide (10) substructure. The enantiomer (?)-3 a (Ki=4.9 μM) of the lead compound (+)-3 a (Ki=31 μM) showed a more than sixfold increased inhibition of the CK2α/CK2β interaction (protein-protein interaction inhibition, PPII) in a microscale thermophoresis (MST) assay. However, (?)-3 a did not show an increased enzyme inhibition of the CK2α2β2 holoenzyme, the CK2α subunit or the mutated CK2α′ C336S subunit in the capillary electrophoresis assay. In the pyrrolocarbazole series, the imide (?)-9 a (Ki=3.6 μM) and the N-methylimide (+)-10 a (Ki=2.8 μM) represent the most promising inhibitors of the CK2α/CK2β interaction. However, neither compound could inhibit enzymatic activity. Unexpectedly, the racemic tetracyclic pyrrolocarbazole (±)-12, with a carboxy moiety in the 4-position, displays the highest CK2α/CK2β interaction inhibition (Ki=1.8 μM) of this series of compounds.

Novel total syntheses of oxoaporphine alkaloids enabled by mild Cu-catalyzed tandem oxidation/aromatization of 1-Bn-DHIQs

Novel total syntheses of oxoaporphine alkaloids such as liriodenine, dicentrinone, cassameridine, lysicamine, oxoglaucine and O-methylmoschatoline were developed. The key step of these total syntheses is Cu-catalyzed conversion of 1-benzyl-3,4-dihydro-isoquinolines (1-Bn-DHIQs) to 1-benzoyl-isoquinolines (1-Bz-IQs) via tandem oxidation/aromatization. This novel Cu-catalyzed conversion has been studied in detail, and was successfully used for constructing the 1-Bz-IQ core.

Environmentally Friendly Synthesis of Indoline Derivatives using Flow-Chemistry Techniques

Flow chemistry proved to be a valuable technique to improve the synthesis route to melanin-concentrating hormone receptor 1 (MCHr1) antagonists with the 1H,2H,3H,4H,5H-[1,4]diazepino[1,7-a]indole scaffold. A one-step route for the heterogeneous catalytic hydrogenation of ethyl 4-(2-nitrophenyl)-3-oxobutanoate for the synthesis of ethyl 2-(2,3-dihydro-1H-indol-2-yl)acetate was developed, and the use of common reducing chemicals was avoided. N-Alkylation of the indoline nitrogen atom was also optimized by using a purpose-built flow reactor and by design of experiment (DoE). Applying an optimal set of parameters allowed us to decrease the amount of carcinogenic 1,2-dibromoethane used by a factor of 10. Additionally, nearly complete conversion was achieved in a fraction of the original reaction time (30 min vs. 4 d); therefore, the productivity (space-time yield) of the flow-reactor system was proven to be ca. 200 times higher than that of the batch process.

Palladium(II)-catalyzed intramolecular tandem aminoalkylation via divergent C(sp3)-H functionalization

(Chemical Equation Presented) We have developed a Pd(II)-catalyzed oxidative tandem aminoalkylation via divergent C(sp3)-H functionalization, a ffording three- and five-membered-ring fused indolines in good yields under two optimized conditions, respectively. The mechanism studies have indicated that the benzylic C - H cleavage involved in the former transformation is the rate-determining step, while the cleavage of amide α-C - H in the latter is not. This is the first example of a Pd-catalyzed tandem reaction involving C(sp3)-H activation without the employment of prefunctionalized reagents (e.g., halogenated and boron reagents) and directing groups, representing a green and economic protocol for the construction of N-containing heterocycles.

A new class of "electro-acid/base"-induced reversible methyl ketone colour switches

Methyl ketone has been designed as a switching unit for electrically addressable molecular colour switches. A newly proposed mechanism of "electro-acid/base" (radical ions)-induced intermolecular proton transfer for the colour switch is proven clearly by cyclic voltammetry (CV), X-ray photoelectron spectroscopy (XPS), infrared spectroscopy (IR) and in situ UV-Vis spectroscopy. A dramatic spectral absorption shift (about 291 nm) is observed during the switching, and blue, yellow and green colours are obtained by adjusting the substituents on the methyl ketone-bridged unit. The in situ "electro-acid/base" is far more convenient than the conventional chemical stimulus of acids or bases for the manipulation of the molecular switching properties. This new switching method and molecular structure manipulation will inspire and accelerate the further development of broad switching materials and applications in ultrathin flexible displays, etc.